GYRE director awarded options on 40,000 shares

GYRE THERAPEUTICS, INC. director David M. Epstein received a grant of stock options to acquire 40,000 shares of common stock.

Rhea-AI Filing Summary

GYRE THERAPEUTICS, INC. director David M. Epstein received a grant of stock options to acquire 40,000 shares of common stock. The options have an exercise price of $5.95 per share and expire on June 10, 2036.

The award was made as a compensation-related grant, with no cash purchase by the insider at grant. According to the terms, the options will vest in 12 equal monthly installments through June 10, 2027, so long as Epstein continues to provide service to the company through each vesting date.

Insider Trade Summary

Grant/Award: 40,000 shares

Grant/Award 1 txn

Insider Epstein David M.

Role Director

Type	Security	Shares	Price	Value
Grant/Award	Stock Option (Right to Buy)	40,000	$0.00	$0.00

Holdings After Transaction: Stock Option (Right to Buy) — 40,000 contracts (Direct)

Footnotes (1)

1. F1. This option represents a right to purchase a total of 40,000 shares of the Issuer's common stock, which will vest in 12 equal monthly installments through June 10, 2027, subject to the Reporting Person's continued service to the Issuer through each vesting date.

Key Figures

Option grant size: 40,000 shares Exercise price: $5.95 per share Expiration date: June 10, 2036 +2 more

5 metrics

Option grant size 40,000 shares Stock Option (Right to Buy) awarded to director

Exercise price $5.95 per share Conversion or exercise price of options

Expiration date June 10, 2036 Option term end date

Shares underlying options 40,000 shares Underlying common stock covered by option

Vesting period 12 monthly installments Through June 10, 2027, subject to continued service

Key Terms

Stock Option (Right to Buy), exercise price, vesting, expiration date, +1 more

5 terms

Stock Option (Right to Buy) financial

"security_title: "Stock Option (Right to Buy)""

exercise price financial

"conversion_or_exercise_price: "5.9500""

The exercise price is the fixed amount at which you can buy or sell an asset, like a stock, when using an options contract. It matters because it helps determine whether exercising the option will be profitable or not, depending on the current market price. Think of it as the set price you agree on today to buy or sell later.

vesting financial

"which will vest in 12 equal monthly installments through June 10, 2027"

Vesting is the process by which you earn full ownership of something, like company stock or a retirement benefit, over time. It’s like earning the right to keep a gift piece by piece the longer you stay with a company, making sure employees stay committed before they receive all the benefits.

expiration date financial

"expiration_date: "2036-06-10T00:00:00.000Z""

The expiration date is the deadline after which a financial contract, such as an option or a futures agreement, is no longer valid or can be exercised. It matters to investors because it determines the timeframe during which they can take action or benefit from the contract, similar to how a coupon or a food item has a limited period of usefulness. Once the expiration date passes, the contract loses its value or ability to be used.

underlying security financial

"underlying_security_title: "Common Stock""

FAQ

AI-generated questions and answers. How Rhea-AI works. Not financial advice.

What did GYRE director David M. Epstein report on this Form 4?

David M. Epstein reported receiving a grant of stock options for 40,000 shares of GYRE common stock. These options are a compensation award, not an open-market stock purchase or sale, and give him the right to buy shares at a fixed exercise price.

How many GYRE shares are covered by Epstein’s new stock options?

The option grant covers 40,000 shares of GYRE common stock. Each option represents the right to buy one share, giving Epstein potential future ownership if he chooses to exercise at the fixed price.

What is the exercise price and expiration date of Epstein’s GYRE options?

The stock options have an exercise price of $5.95 per share and expire on June 10, 2036. Epstein can only benefit economically if GYRE’s stock trades above this price before expiration.

How do the vesting terms work for Epstein’s GYRE option award?

The 40,000-share option grant vests in 12 equal monthly installments through June 10, 2027. Vesting is contingent on Epstein’s continued service to GYRE for each monthly vesting date during this period.

Did David M. Epstein buy or sell GYRE shares in the market?

No, the Form 4 shows a grant of stock options, not a market trade. This is a compensation-related acquisition, giving Epstein rights to purchase shares later rather than reflecting an immediate buy or sell.

AI-generated analysis. How Rhea-AI works. Not financial advice.

Form 4 Insider Transactions: What Each Field Means →

See more from StockTitan in Google Search and AI answers. Adds StockTitan as a preferred source · opens Google

Add on Google Not now

Accepted by SEC EDGAR 06/30/2026 - 06:17 PM EDT Learn about SEC filing dates

SEC Form 4

FORM 4

UNITED STATES SECURITIES AND EXCHANGE COMMISSION
Washington, D.C. 20549

STATEMENT OF CHANGES IN BENEFICIAL OWNERSHIP

Filed pursuant to Section 16(a) of the Securities Exchange Act of 1934
or Section 30(h) of the Investment Company Act of 1940

OMB APPROVAL

OMB Number:			3235-0287
Estimated average burden
hours per response:			0.5

Check this box if no longer subject to Section 16. Form 4 or Form 5 obligations may continue. See Instruction 1(b).

Check this box to indicate that a transaction was made pursuant to a contract, instruction or written plan for the purchase or sale of equity securities of the issuer that is intended to satisfy the affirmative defense conditions of Rule 10b5-1(c). See Instruction 10.

1. Name and Address of Reporting Person^*

Epstein David M.

(Last) (First) (Middle)

C/O GYRE THERAPEUTICS, INC.

12730 HIGH BLUFF DRIVE, SUITE 250

(Street)

SAN DIEGO CALIFORNIA 92130

(City) (State) (Zip)

UNITED STATES

(Country)

2. Issuer Name and Ticker or Trading Symbol
GYRE THERAPEUTICS, INC. [ GYRE ]

5. Relationship of Reporting Person(s) to Issuer
(Check all applicable)

X	Director		10% Owner
	Officer (give title below)		Other (specify below)

2a. Foreign Trading Symbol

3. Date of Earliest Transaction (Month/Day/Year)
06/10/2026

6. Individual or Joint/Group Filing (Check Applicable Line)

X	Form filed by One Reporting Person
	Form filed by More than One Reporting Person

4. If Amendment, Date of Original Filed (Month/Day/Year)

Table I - Non-Derivative Securities Acquired, Disposed of, or Beneficially Owned
1. Title of Security (Instr. 3)	2. Transaction Date (Month/Day/Year)	2A. Deemed Execution Date, if any (Month/Day/Year)	3. Transaction Code (Instr. 8)		4. Securities Acquired (A) or Disposed Of (D) (Instr. 3, 4 and 5)			5. Amount of Securities Beneficially Owned Following Reported Transaction(s) (Instr. 3 and 4)	6. Ownership Form: Direct (D) or Indirect (I) (Instr. 4)	7. Nature of Indirect Beneficial Ownership (Instr. 4)
			Code	V	Amount	(A) or (D)	Price

Table II - Derivative Securities Acquired, Disposed of, or Beneficially Owned (e.g., puts, calls, warrants, options, convertible securities)
1. Title of Derivative Security (Instr. 3)	2. Conversion or Exercise Price of Derivative Security	3. Transaction Date (Month/Day/Year)	3A. Deemed Execution Date, if any (Month/Day/Year)	4. Transaction Code (Instr. 8)		5. Number of Derivative Securities Acquired (A) or Disposed of (D) (Instr. 3, 4 and 5)		6. Date Exercisable and Expiration Date (Month/Day/Year)		7. Title and Amount of Securities Underlying Derivative Security (Instr. 3 and 4)		8. Price of Derivative Security (Instr. 5)	9. Number of derivative Securities Beneficially Owned Following Reported Transaction(s) (Instr. 4)	10. Ownership Form: Direct (D) or Indirect (I) (Instr. 4)	11. Nature of Indirect Beneficial Ownership (Instr. 4)
				Code	V	(A)	(D)	Date Exercisable	Expiration Date	Title	Amount or Number of Shares
Stock Option (Right to Buy)	$5.95	06/10/2026		A		40,000		(1)	06/10/2036	Common Stock	40,000	$0	40,000	D

Explanation of Responses:

1. This option represents a right to purchase a total of 40,000 shares of the Issuer's common stock, which will vest in 12 equal monthly installments through June 10, 2027, subject to the Reporting Person's continued service to the Issuer through each vesting date.

	/s/ Thomas Eastling, as attorney-in-fact for David M. Epstein	06/30/2026
	** Signature of Reporting Person	Date
Reminder: Report on a separate line for each class of securities beneficially owned directly or indirectly.
* If the form is filed by more than one reporting person, see Instruction 4 (b)(v).
** Intentional misstatements or omissions of facts constitute Federal Criminal Violations See 18 U.S.C. 1001 and 15 U.S.C. 78ff(a).
Note: File three copies of this Form, one of which must be manually signed. If space is insufficient, see Instruction 6 for procedure.
Persons who respond to the collection of information contained in this form are not required to respond unless the form displays a currently valid OMB Number.
* Form 4: SEC 1474 (03-26)